FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies
Explainer: What’s behind FDA’s concern that a cancer-fighting cell therapy can also cause the disease?
A Cutting-Edge Cancer Treatment May Cause Cancer. The FDA Is Investigating